Innate Biologics

About Innate Biologics

This author has not yet filled in any details.
So far Innate Biologics has created 4 blog entries.

United States Patent and Trademark Office Issues Innate Biologics™ E3 Ligase Effector Protein Patent

PHILADELPHIA, PA — September 23, 2019 —Innate Biologics™ has been granted patent protection for its novel E3 Ligase recombinant protein platform that targets inflammatory signaling pathways.

United States Patent and Trademark Office Issues Innate Biologics™ E3 Ligase Effector Protein Patent2019-09-27T00:21:11-04:00

Exclusive License Agreement with The Wistar Institute for Paired Protein Platform

Philadelphia, PA — June 25, 2019 — Innate Biologics, LLC has entered into an exclusive license agreement with The Wistar Institute, an internationally recognized leader in biomedical research, to co-owned patent rights related to a unique anti-inflammatory protein platform resulting from a 2018 research collaboration between Innate Biologics and Wistar.

Exclusive License Agreement with The Wistar Institute for Paired Protein Platform2019-09-27T00:13:15-04:00

Innate Biologics and The University of Münster Medical Enter Into Broad Multi-Year Collaboration Agreement

Münster, Germany and Philadelphia, US—June 21, 2019 Innate Biologics™ has entered into a multi-year collaboration agreement with one of Germany’s leading scientific and research institutes with a focus on skin applications.

Innate Biologics and The University of Münster Medical Enter Into Broad Multi-Year Collaboration Agreement2019-09-27T23:06:21-04:00